Identifying and validating causal genetic alterations in human breast cancer

Breast Cancer Research and Treatment

Volumn 78, Issue 3, 2003, Pages 285-287

  Ethier, Stephen P ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Breast cancer oncogene; Gene amplification

Indexed keywords

AMPLICON; BREAST CANCER; CANCER GENETICS; CANCER GROWTH; CANCER RESEARCH; GENE ACTIVATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC DISORDER; HUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; VALIDATION PROCESS;

BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; ONCOGENES;

EID: 0037738898     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023078722316     Document Type: Review

References (14)

1. Ethier SP: Growth factor synthesis and human breast cancer progression. J Natl Cancer Inst 87: 964-973, 1995
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987
3. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SAW, Killander D, McGuire WL: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332-4337, 1990
4. Woods lgnatoski KM, LaPointe AJ, Radany EH, Ethier SP: ErbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology 140: 3615-3622, 1999
5. Woods Ignatoski KM, Maehama T, Markwart SM, Dixon JE, Livant DL, Ethier SP: ErbB-2 overexpression confers PI 3′-kinase-dependent invasion capacity on human mammary epithelial cells. Br J Cancer 82: 666-674, 2000
6. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54: 105-115, 1988
7. Siegel PM, Dankort DL, Hardy WR, Muller WJ: Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14: 7068-7077, 1994
8. Leyland-Jones B, Smith I: Role of herceptin (r) in primary breast cancer: views from North America and Europe. Oncology 61: 83-91, 2001
9. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES: Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clinical Cancer Res 8: 17201730, 2002
10. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J: Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxombicin in breast cancer. Am J Pathol 156: 839-847, 2000
11. Fiddes RJ, Campbell DH, Janes PW, Sivertsen SP, Sasaki H, Wallasch C, Daly RJ: Analysis of Grb7 recruitment by heregulin-activated ErbB receptors reveals a novel target selectivity for ErbB3. J Biol Chem 273: 7717-7724, 1998
12. Han DC, Shen TL, Guan JL: Role of Grb7 targeting to focal contacts and its phosphorylation by focal adhesion kinase in regulation of cell migration. J Biol Chem 275: 28911-28917, 2000
13. Tanaka S, Sugimachi K, Kawaguchi H, Saeki H, Ohno S, Wands JR: Grb7 signal transduction protein mediates metastatic progression of esophageal carcinoma. J Cell Physiol 183: 411-415, 2000
14. Woods Ignatoski K, Ethier SP: Constitutive activation of pp 125fak in eleven newly isolated breast cancer cell lines. Breast Cancer Res Treatment 54: 173-182, 1999